Trial Profile
Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary) ; Reboxetine
- Indications Abdominal pain; Major depressive disorder
- Focus Pharmacodynamics; Therapeutic Use
- 26 May 2010 Planned end date changed from 1 Jun 2009 to 1 Apr 2011 as reported by ClinicalTrials.gov.
- 01 Aug 2006 Status change
- 26 Nov 2005 New trial record.